International registry for patients with newly diagnosed peripheral T-cell lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect data on patients with newly diagnosed peripheral T-cell lymphoma (PTCL) to improve understanding of the disease's prognosis and treatment strategies. It builds on previous research by the International T-cell Non-Hodgkin's Lymphoma Study Group and focuses on the clinical relevance of the new WHO Classification, the role of FDG-PET in staging, and the genomic landscape of different PTCL subtypes. The study will gather routine clinical data and tissue samples to enhance knowledge of PTCL biology and identify potential therapeutic targets.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Previously-untreated patients with de novo diagnosis of peripheral T-cell or NK/T-cell lymphoma:

   * T-cell large granular lymphocytic leukaemia;
   * Chronic lymphoproliferative disorder of NK cells;
   * Aggressive NK-cell leukaemia;
   * Adult T-cell leukaemia/lymphoma;
   * Extranodal NK/T-cell lymphoma, nasal type;
   * Intestinal T-cell lymphoma;
   * Hepatosplenic T-cell lymphoma;
   * Subcutaneous panniculitis-like T-cell lymphoma;
   * Peripheral T-cell lymphoma, not otherwise specified;
   * Angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper cell origin;
   * Anaplastic large cell lymphoma, ALK-positive;
   * Anaplastic large cell lymphoma, ALK-negative;
   * Breast implant-associated anaplastic large cell lymphoma.
2. Age 18 and over;
3. Tissue biopsy adequate for diagnosis and classification and available for centralized review;
4. Clinical data including baseline information on disease localization and laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating for at least 2 years are requested;
5. Written informed consent.

Exclusion Criteria:

1. Diagnosis of:

   * EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood
   * Mycosis fungoides;
   * Sézary syndrome;
   * Primary cutaneous CD30-positive T-cell lymphoproliferative disorders;
   * Primary cutaneous peripheral T-cell lymphomas, rare subtypes;
   * T-cell lymphoblastic lymphoma/leukemia
   * T-cell prolymphocitic leukemia
2. Age \< 18.

Where it's running

• IRCCS Istituto Tumori "Giovanni Paolo II"
  Bari, Italy Recruiting
• Cluj Napoca_Ion Chiricuta Oncology Institute
  Cluj-Napoca, Romania Recruiting
• National Cancer Institute
  Kiev, Ukraine Recruiting
• Stanford University
  Stanford, California, United States Not yet recruiting
• Palermo_La Maddalena
  Palermo, Italy Not yet recruiting
• Terni-Santa Maria
  Terni, Italy Not yet recruiting

Study contacts

• Principal investigator: Attilio Guarini, MD — U.O. Ematologia, IRCCS Istituto Tumori "Giovanni Paolo II"
• Study coordinator: Martina Manni, MSc, PhD
• Email: marmanni@unimore.it
• Phone: +390594223284

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• XNW5004 with CHOP/CHOEP in Untreated Peripheral T-Cell Lymphoma

  This study tests XNW5004 together with CHOP or CHOEP in adults with newly diagnosed peripheral T-cell lymphoma to see if the combination is safe and active.

  Recruiting Phase 1/2 Evopoint Biosciences Inc. · Shanghai, Shanghai Municipality · NCT07730515

• Adaptive dual-target CAR-T therapy for relapsed or refractory blood cancers

  This trial will test whether matching a patient's cancer markers to one of several dual-target CAR-T therapies can work and be safe for adults whose blood cancer has come back or not responded.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07523555

• Treatment options for peripheral T‑cell lymphoma after no response to first‑line therapy

  This project will try allogeneic stem cell transplant versus other salvage treatments for adults with peripheral T‑cell lymphoma who did not respond to first‑line chemotherapy.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07470996

• Golidocitinib versus placebo as maintenance treatment for PTCL patients in remission after first-line chemotherapy

  This trial tests whether taking golidocitinib every other day can help keep peripheral T‑cell lymphoma from coming back in adults who responded to first‑line chemotherapy but cannot have a stem cell transplant.

  Recruiting Phase 3 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07414758

• Cidabenamine plus azacitidine to prevent post-transplant progression in high-risk peripheral T‑cell lymphoma

  This trial will test whether adding cidabenamine to azacitidine after allogeneic stem cell transplant can help prevent progression in adults with high‑risk peripheral T‑cell lymphoma.

  Recruiting Phase 2/3 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality · NCT07389616

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.